Results 51 to 60 of about 22,958 (212)

The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO)

International Journal of Cancer, Volume 159, Issue 7, Page 1633-1641, 1 October 2026.
ABSTRACT The recently published ONKOPEDIA guideline on myelofibrosis, issued under the auspices of the German Society of Hematology and Oncology (DGHO), provides an updated, evidence‐based framework for the diagnosis and management of this rare, chronic myeloproliferative neoplasm.
Martin Griesshammer, Haifa Kathrin Al‐Ali, Gabriela M. Baerlocher, Konstanze Döhner, Steffen Koschmieder, Nicolaus Kröger, Petro E. Petrides, Dominik Wolf, Florian H. Heidel   +8 more
wiley   +1 more source

Patients with Essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis [PDF]

, 2002
A significant proportion of patients with Essential Thrombocythaemia (ET) have thrombotic complications which have an important impact upon the quality, and duration of their life.
Machin, S.J., C.N. Harrison, P. Carr, Mackie, I., Donohoe, S., S.J. Machin, S. Donohoe, I. Mackie, M. Dave, Harrison, C.N., Dave, M., Carr, P.   +11 more
core   +1 more source

Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia

Haematologica, 2013
Subclones homozygous for JAK2V617F are more common and larger in patients with polycythemia vera compared to essential thrombocythemia, but their role in determining phenotype remains unclear.
Anna L. Godfrey, Edwin Chen, Francesca Pagano, Yvonne Silber, Peter J. Campbell, Anthony R. Green   +5 more
doaj   +1 more source

Clinical and Laboratory Characterization of Acquired Von Willebrand Syndrome

American Journal of Hematology, Volume 101, Issue 9, Page 2147-2156, September 2026.
ABSTRACT Acquired von Willebrand Syndrome (AVWS) is a rare bleeding disorder characterized by quantitative or qualitative defects of von Willebrand factor (VWF) in patients without a personal or family history of bleeding. It is frequently associated with systemic diseases, particularly lymphoproliferative disorders (LPDs) and myeloproliferative ...
Alessandro Ciavarella, Luciano Baronciani, Omid Seidizadeh, Paola Colpani, Elio Ingenito, Daniele Cattaneo, Maria Teresa Pagliari, Addolorata Truma, Alessandra Iurlo, Simona Maria Siboni, Flora Peyvandi   +10 more
wiley   +1 more source

Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post‐essential thrombocythemia myelofibrosis: A case report

eJHaem
Paroxysmal nocturnal hemoglobinuria (PNH) results from the loss of erythrocyte surface proteins, leading to complement activation and its spectrum of effects.
Mahija Cheekati, KarLeung Siu, Rachel Ochs   +2 more
doaj   +1 more source

Late‐Onset Chorea in JAK2‐Associated Essential Thrombocythemia [PDF]

, 2021
Somatic mutations in JAK2 are associated with chronic myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis (PMF).
Mulroy, E, Di Lazzaro, G, Giulia Di Lazzaro, Koya Kutty, Shahedah, Shahedah, KK, Di Lazzaro, Giulia, Magrinelli, F, Mulroy, Eoin, Latorre, A, Anna Latorre, Shahedah Koya Kutty, Francesca Magrinelli, Bhatia, KP, Latorre, Anna, Eoin Mulroy, Bhatia, Kailash P, Kailash P. Bhatia, Magrinelli, Francesca   +17 more
core   +1 more source

Modern Approaches to Diagnosis and Treatment of Essential Thrombocythemia: Literature Review and Own Experience

Клиническая онкогематология, 2015
Objective. The aim of our study was to present literature data and own experience about epidemiology, terminology, etiology and pathogenesis of еssential thrombocythemia. Methods.
K. M. Abdulkadyrov, Vasilii Anatol’evich Shuvaev, I. S. Martynkevich   +2 more
doaj   +1 more source

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 753-761, September 2026.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2016
Introduction. A high platelet count, or thrombocytosis, is either a reactive process or a result of a myeloproliferative disorder. Ankylosing spondylitis is a chronic inflammatory rheumatic disease affecting the spine and sometimes peripheral ...
Zeremski Vanja, Savić Aleksandar, Ilić Tatjana, Milošević Ivana, Maksimović Marina, Vučković Biljana   +5 more
doaj   +1 more source

Langerhans Cell Histiocytosis in Adults: A Canadian Multicenter Case Series

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Langerhans cell histiocytosis (LCH) is a rare clonal myeloid neoplasm. Canadian data on clinical characteristics, molecular profile, and treatment outcomes is limited. This study aims to report the initial experience of a Canadian rare diseases program, reflecting “real‐world” diagnostic pathways, referral patterns, and treatment heterogeneity
Stephanie Quon, Yaswanta Gummadi, Ibrahim Elsharawi, Jessica Dobson, Mariam Goubran, Ryan J. Stubbins, Eli L. Diamond, Luke Y. C. Chen   +7 more
wiley   +1 more source